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Abstract 
Background: Chronic pain, smoking, and opioid use, contribute to a significant economic 
burden in the United States. Chronic pain affects all aspects of life, and is influenced by the use 
of cigarettes and opioids alike. Researchers suggest that there is a higher use of cigarettes and 
opioids in individuals with chronic pain. Chronic pain can promote smoking and smokers are 
more likely to use opioids. With the evidence that patients who smoke a higher number of 
cigarettes per day report higher pain, it is possible that smoking may be a stress-reducing 
behavioral response related to pain.  Moreover, higher frequency and intensity of pain, can 
contribute to a higher dose of opioid therapy. Hence, it is critical to understand smoking 
behaviors and opioid use in managing pain among those with chronic pain.   
Purpose: The purpose of this project was to examine the relationship between smoking and 
opioid use in managing pain among patients at a chronic pain management clinic.  
Methods: This project was a single-center, retrospective chart review to evaluate the relationship 
between smoking, chronic pain, and the use of opioids. The project was conducted over a six-
month time frame (from June 1, 2017- November 30, 2017) and the sample consisted of 37 
subjects: 7 smokers and 30 non-smokers. Information on smoking history, opioid medication 
use, and perceived pain using the Global Pain Scale (GPS) was obtained from attendants at a 
pain clinic. A two-sample t-test was used to compare differences in average pain scores and 
morphine milligram equivalent (MME) for opioid use between smokers and non-smokers.  
Results: The average pain rating for the entire project population (n=37) was six, with an 
average GPS score of 31. The average acceptable pain level was five. When the data was 
analyzed separately, smokers were found to have an average GPS score of 30 and an 
average pain rating of 6.7/10, while non-smokers were found to have an average GPS of 21 
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and an average pain score of 6/10; but these differences were not statistically significant. 
The MME was higher for smokers than for non-smokers (26.4mg MME vs. 21.9mg MME), but 
these differences were not statistically significant. 
Conclusion: Patients with chronic pain who smoke have a higher pain rating compared to non-
smokers, therefore, possibly requiring higher use of opioids.  Providers are encouraged to use 
evidence-based smoking cessation treatment to assist their patients who smoke. To improve 
overall patient health, patient experience, and quality of life, providers should screen, advise, and 
counsel patients with chronic pain to abstain from smoking, which may ultimately result in 
decreased opioid need and use.  
 
Keywords: Smoking, chronic pain, opioids  
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A Retrospective Analysis Evaluating the Relationship Between Tobacco use and Pain Perception 
using the Global Pain Scale (GPS) in Opioid Dependent Adults  
Background 
Chronic pain and tobacco use are prevalent healthcare issues faced by primary care 
providers.  Tobacco use is the leading cause of preventable death in the United States, 
resulting in an estimated 480,000 deaths and $19 billion spent on health care annually 
(Nguyen, 2016). Similarly, chronic pain, when treated with opioids has been associated 
with opioid misuse and contributes to the problem of opioid addiction (Gaskin & Richard, 
2012). There is developing evidence that a relationship between cigarette smoking and 
opioids exists. Young-Wolff et al., (2017) suggests the there is a higher use of cigarettes and 
opioids in individuals with chronic pain. The purpose of this project was to examine the 
relationship between smoking and prescribed opioids among patients with chronic pain.. 
Chronic pain has been found to coincide with increased smoking behavior (Zale et 
al., 2016; Young-Wolff et al., 2017). Despite extensive research, little is known about this 
relationship. Though nicotine and opioids share a similar addiction pathway within the 
brain, how this manifests remains in question. However, it is clear that Kentucky ranks 
higher than the national average in both tobacco and opioid use, therefore healthcare 
providers must address both forms of addiction (Nguyen, 2016). 
Addiction 
Addiction is based on the principle of pleasure to the extent that it can alter the 
structure and function of the brain (Volkow & Morales, 2015). The reward center of the brain 
is the ventral tegmental area (VTA) located in the brainstem. The VTA is a dopamine-producing 
area strongly associated with motivation and reward. Dopamine creates a pleasing and enjoyable 
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sensation, hence, a dopamine producing action (ie smoking, gambling) can easily become 
habitual (Sutherland et al., 2016). Over time, exposure to an addictive substance or behavior can 
alter the brain chemistry, requiring more dopamine to achieve the same “high” effect.  
Nicotine, the psychoactive substance in tobacco products, acts on acetylcholine receptors 
and potentiates a release of dopamine in the brain (Abburi et al., 2017). This release of 
dopamine can result in anti-nociceptive properties, thereby exhibiting an analgesic effect in 
the body (Abburi et al., 2017; Goesling et al., 2015). In a similar fashion, chronic pain relief 
from opioids can lead to abuse when it hijacks the reward circuitry of the brain, increasing 
the reliance on opioids as a means to ameliorate pain. Addiction to opioids is characterized 
by the inability to abstain from the substance. This increasing reliance on opioids leads to 
dependence, a physiological need to take the drug, accompanied by tolerance, requiring a 
higher dose to achieve the same effect. Without continual use of the substance, withdrawal 
symptoms can occur. Opioid addiction can include physical dependence, but there is a 
dysfunction in emotional response resulting in compulsive substance use despite harm 
(Goesling et al., 2015). 
Tobacco Use 
Smoking is the leading cause of preventable death in the United States with an 
economic health burden of $19 billion (Nguyen, 2016; USDHHS, 2014). In Kentucky, 
twenty-six percent of adults use tobacco, ranking second in the nation for prevalence of 
tobacco use, behind West Virginia at 26.9 percent (Odani et al., 2018). Tobacco use is an 
addictive behavior causing damage to nearly every organ in the body. It contributes to many 
health problems including respiratory and cardiovascular disease, stroke, and cancer (Odani 
et al., 2018; USDHHS, 2014).   
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Nicotine impairs blood flow and oxygenation to tissues at the cellular level. 
Furthermore, nicotine has also been shown to accelerate intervertebral disc degeneration 
resulting in higher instance of chronic back pain (Young-Wolff et al., 2017). Although the 
nicotine in tobacco products may have some analgesic effect on pain, the other constituents of 
tobacco products are known to have severe detrimental effects on most body systems, which can 
result in chronic pain (USDHHS, 2014). Evidence suggests the link between pain and smoking 
can be associated with more intense pain and pain interference (Goesling et al., 2015). 
Tobacco Quit Strategies 
Healthcare providers (HCP) have been strongly encouraged to address nicotine use at 
every healthcare visit (Kruger et al., 2016). The 5 A’s is a behavioral counseling framework 
used to engage patients in tobacco treatment (Laschober et al., 2015 & Aveyard et al., 2012). The 
acronym helps guide HCPs to: ask patients about their tobacco use, advise them to quit, assess 
willingness to quit, assist in quitting, and arrange for follow-up contact. Implementing this 
technique may help guide providers to engage patients in tobacco cessation strategies. 
Researchers also suggest that providers should take environmental, cognitive and behavioral 
factors into account when developing a plan of care for patients who smoke (Laschober et al., 
2015).  Using the 5 A’s as a brief intervention by a medical provider can increase quit attempts 
for patients in diverse clinical settings (Kruger et al., 2016; Laschober et al., 2015).   
There are seven FDA approved medications (Varenicline, Bupropion, nicotine patch, 
nicotine gum, nicotine lozenge, and nicotine nasal spray) that have been shown to increase 
the success of a smoking cessation attempt. When behavioral therapy is combined with 
Nicotine Replacement Therapy (NRT), the success of smoking cessation is optimized (Fiore 
et al, 2008). The guideline used by the CDC indicates that medication plus counseling by a 
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healthcare provider increases the likelihood of tobacco abstinence by almost a third than if 
one technique was used alone (Fiore et al., 2008). Brief interventions combined with the use 
of smoking cessation medications can greatly improve tobacco cessation among patients in 
primary care settings (Fiore et al., 2008; Aveyard et al., 2012). 
Opioid use 
Opioids have had a long history for management of both acute and chronic pain. 
Unfortunately, opioids have been misused by those without chronic pain resulting in 
addiction. In 2016, Kentucky reported 33.1 per 100,000 deaths related to the misuse of 
opioids. This was significantly higher than the national average of 16.3 per 100,000 deaths 
(Hedegaard, Warner & Minino, 2017). While morphine was the most common detectable 
substance related to overdose fatalities, oxycodone accounted for 19 percent of deaths and 
hydrocodone accounted for 16 percent of deaths by overdose (Hedegarrd et al., 2017).  
Despite the association between opioids and addiction, there is a role for opioids in the 
management of chronic pain. The current CDC guideline (Figure 10) recommends that HCPs 
first engage in nonpharmacologic therapy as the preferred treatment for chronic pain (Dowell, 
Haegerich, & Chou, 2016). Opioid treatment should be considered for those patients who have 
chronic renal failure, cannot be prescribed NSAIDs, fibromyalgia, and certain types of arthritis. 
The guideline recommends that clinicians prescribe immediate release opioids at the 
lowest effective dosage. Morphine milligram equivalents (MME) are used to standardize the 
dosage of various opioids as a constant measure. Caution must be used when increasing dosages 
greater than 50 MME, as this puts the patient at higher risk for opioid misuse (Dowell et al., 
2016). Additionally, the CDC recommends that risk factors for opioid related harms are 
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evaluated periodically, along with urine drug screens, and the use of the state’s opioid 
monitoring system (Dowell et al., 2016).  
Chronic Pain 
Chronic pain is defined as pain lasting longer than six months and affects over 100 
million Americans (IASP, 2017; Nahin, 2015). The International Association for the Study 
of Pain (2017) recognizes it as a multidimensional sensation. Chronic pain affects 
morbidity, sleep, cognition, mobility, psychosocial behaviors, and overall functional status. 
The most common types of chronic pain seen in primary care include low back pain, headache 
and pain caused by conditions such as fibromyalgia, multiple sclerosis and diabetes (Orhurhu, 
Pittelkow, & Hooten, 2015). It is estimated that the United States spends $261-300 billion in 
healthcare costs related to chronic pain (Gaskin, & Richard, 2012). The economic burdens of 
managing chronic pain have a significant impact on healthcare costs in the United States.  
The Global Pain Scale (GPS) is a tool used to quantify pain perception (Figure 1). There 
are four areas addressed in this tool regarding the patient’s pain, feelings, clinical outcomes and 
activities.  A higher number reported on the GPS is associated with a higher instance, frequency 
and intensity of pain. A composite score allows comparisons between visits to monitor the 
patient’s progress and effectiveness of treatment (Gentile et al., 2011) This tool is easily 
administered and can be completed by the patient. The GPS was found to have high criterion 
validity and high construct validity in patients with chronic pain (Gentile et al., 2011).  
The Kentucky All Schedule Prescription Electronic Reporting (KASPER) is an 
electronic system used by pharmacists and clinicians to monitor opioid prescribing 
(Blumenschein et al., 2010).  Kentucky House Bill 1 (HB1), passed in 2012, was designed to 
regulate the prescribing of controlled substances and prescription drug abuse in Kentucky 
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(Freeman, Goodin, Troske, & Talbert, 2015). Kentucky HB1 requires all patients who are 
prescribed a controlled substance in the state to abide by a ‘drug contract’ signed by both 
the patient and the provider at the start of treatment. The agreement (Figure 3) adheres to 
the conditions for continual prescribing and requires an annual urine drug test, in addition 
to a clinical diagnosis, physical exam, behavioral screening, and a KASPER report at each 
visit (Freeman et al., 2015).  
Using the Health Belief Model (HBM) and its constructs, a practitioner can assess what 
personal or environmental events prompt behavior change for the patient, thus, determining the 
self-efficacy and likelihood for the patient to adhere to and maintain a health promotion practice 
(Green & Murphy, 2014). The goal of the first construct of perceived severity helps the 
patient to understand how tobacco use contributes to chronic pain and opioid use. Through 
motivational interviewing, HCPs can help patients identify perceived facilitators and 
barriers, contributing to smoking cessation in relation to chronic pain.  
Individually, smoking behavior and opioids that are prescribed for chronic pain 
management contribute to rising healthcare costs and patient mortality (Hooten et al., 2014). 
Addressing these additive problems necessitate that HCPs assess how patients use these 
drugs as well as their perception of the relationship of these two to each other. As these 
addictive problems are particularly high in Kentucky, exploring the relationship between 
them is of utmost importance.   
Methods 
Objectives/Specific aims 
An urban primary care clinic developed a sub-clinic in response to the clinical 
treatment guidelines developed by the American Pain Association (APA). The Chronic 
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Opioid Analgesic Therapy (COAT) clinic was established for opioid surveillance. The 
COAT clinic also met the APA guidelines and Kentucky House Bill 1 regarding opioid use. 
Patients are seen once a month to assess and evaluate the effectiveness of their treatment. 
The purpose of this project was to examine the relationship between smoking and chronic 
pain management in patients at the COAT clinic.  
The aims for this study included:  
1. Examine the pain scores (using the GPS) of all patients managed in the COAT 
clinic, including both smokers and non-smokers.  
 
2. Examine the differences in pain level (current pain level, GPS scores, and 
acceptable pain level) and opioid use (morphine equivalents) between smokers 
and non-smokers. 
 
Setting 
This project took place within an urban primary care clinic in a southern city. The 
COAT clinic was offered twice a month, had two primary providers, a physician and a 
nurse practitioner, as well as a registered nurse to assist the patients. Appointments lasted 
approximately 15 minutes and patients were given a 30-day supply of their medication via 
written prescription.  
Population 
A total of 37 male and female subjects, all over the age of 18, were enrolled in the 
COAT clinic. These patients had a clinically diagnosed reason for needing a controlled 
substance, such as tramadol or hydrocodone, to help control their pain. Inclusion criteria 
were: admittance into the COAT clinic between June 1, 2017- November 30, 2017, adults 
over the age of 18, a clinically diagnosed pain condition, and adherence to the COAT clinic 
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contract. Exclusion criteria were dismissal from the COAT clinic or failure to adhere to the 
medication contract (for example, having a positive urine drug screen). 
Data Collection 
 A retrospective chart review was conducted over a six-month time frame: June 1, 2017- 
November 30, 2017. Approval from the University of Kentucky Institutional Review Board 
(IRB) was obtained prior to the collection of data. The data was extracted from the electronic 
health record and placed into a secure, web-based application. A crosswalk table was designed 
with 37 patient records assigned to a study number so that no patient identifying information was 
used during the data collection and analysis process.  These study numbers replaced medical 
record numbers on all electronic data collection forms and electronic data used in data collection 
and data analysis as to protect patient privacy.  
Measures 
Data were collected via patient chart review. The following variables were included: 
demographics, smoking status, comorbidities, and pain outcomes.  
 Demographic variables included age (years), gender (male vs. female), co-morbidities, 
and diagnosis. Smoking status was based on documented self-reported current smoking (yes vs 
no) at each clinic visit. Four co-morbidities were evaluated based on documented clinical 
diagnosis: Hypertension, hyperlipidemia, diabetes mellitus (DM), and anxiety/depression. Pain 
medications and amount prescribed in the COAT clinic (tramadol vs. hydrocodone vs. 
oxycodone), pain level at the time of COAT clinic appointment (on a scale of 1-10), average 
GPS score (1-100), and acceptable Pain Level (on a scale of 1-10).  
The average scores on the GPS, pain level at the time of appointment and acceptable pain 
level were determined based on scores obtained over six-time points. Opioid use was converted 
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to oral morphine milligram equivalent (MME) doses according to the equianalgesic dose chart 
used by the CDC (Table 4) (Dowell et al., 2016).    
Data Analysis 
Descriptive statistics, including means and standard deviations or frequency distributions, 
were used to summarize study variables. The variables included age, gender, smoking status 
(yes/no), acceptable pain level (1-10), pain level at the time of the COAT clinic appointment (1-
10) and average GPS score (1-100) over the six-month time frame.  Additional patient 
characteristics were co-morbidities, pain-related diagnoses, prescribed opioid, and side effects.  
Of the 37 patients who met the inclusion criteria for this project, only seven were 
smokers. Data was analyzed for the entire group and then for a sub-group, comparing seven 
smokers to a matched sample of seven non-smokers. Therefore, the emphasis of the analysis is 
on descriptive statistics. MME were used as a constant to standardize the dosage of various 
opioids. A two-sample t-test was used to compare differences in average pain scores and MME 
for opioid use between smokers and non-smokers. Data analysis was conducted using SPSS, 
version 24 with an alpha level of .05. 
Results 
Sample characteristics 
A total of 37 patients were identified for this project, where 19% (n=7) were 
identified as smokers and 81% (n=30) were non-smokers. The mean age was 62. Over half 
of the population was female (76%) (Table 1). The average pain rating at the time of the 
COAT clinic appointment for all participants (n=37) was six out of ten, with an average 
GPS score of 31, and the average acceptable pain level was five out of ten (see Table 1).  
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Clinical diagnoses included arthritis, generalized pain, Degenerative Disc Disease, 
arthropathy, neuropathy, cervicalgia, and other diagnoses such as May Turner syndrome and 
Charcot-Marie Syndrome (Figure 9). Arthritis was found to be the most common diagnosis for 
smokers and non-smokers. The narcotics prescribed to the patients included Tramadol 50mg, 
Hydrocodone 10mg, Hydrocodone 7.5mg, Hydrocodone 5mg, and Oxycodone 10mg. Side 
effects of pain medications included asymptomatic, constipation, drowsiness, pruritus, increased 
sweating, insomnia, sexual dysfunction, and fatigue.  Smokers were found to have more side 
effects than non-smokers in the sub-group (5 vs. 3). The charting reflected two of the seven 
smokers were interested in smoking cessation.  
In Figure 8, a list of co-morbidities is provided comparing the smokers and non-
smokers. Smokers were found to have higher instance of neuropathy (29% vs 7%) and 
depression/anxiety (71% vs. 33%). There were no other differences in co-morbidities noted. 
A comparison of pain location was also explored, with smokers reporting a higher level of 
lower extremity pain than non-smokers (86% vs. 33%).  
Smokers had higher levels of pain at the time of each appointment and higher GPS 
scores compared to non-smokers (Table 2). There were no differences in acceptable pain 
levels between smokers and non-smokers. In a similar fashion, the MME was higher for 
smokers as compared to non-smokers (26.4 MME vs. 21.9 MME). The relationship was not 
statistically significant (p=0.42).  
Matched Control 
A sub-group (n=7) was identified from the original non-smoking group (n=30) for 
the purpose of a matched comparison. The same sample of smokers was used when 
comparing these two sub-groups (Table 3). Both groups consisted of one male and six 
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females and had an average age of 62. Arthritis was the prominent diagnosis for both groups 
(nine out of fourteen).  
The average MME for the smokers was 26.4 MME vs.19.6 MME for the non-
smoking sub-group. The smokers had an average GPS score of 34.2 and an acceptable pain 
rating of five out of ten. The non-smoking sub-group had an average GPS of 27.3 and an 
acceptable pain rating of six out of ten. Both groups reported a pain level of seven out of ten 
at the time of their COAT appointments. There was no statistical difference in any of these 
variables.  
Discussion 
Key Findings 
Although the sample size was small, some of the project findings are of clinical 
relevance. Primarily, there were two main outcomes between smokers and non-smokers on 
chronic opioids, 1) smokers used higher doses of opioids and 2) there was a higher instance of 
anxiety and depression among smokers. The relationship between pain, smoking, and opioids is 
concerning and should be recognized for the potential interactions by HCPs. 
The entire sample in this project mirrored demographics noted in the literature reviewed. 
For example, women have been found to have higher occurrence of chronic pain for a variety of 
reasons. Female hormones may increase pain sensitivity, and greater nerve density could result 
in intense pain severity in women (Young-Wolff et al., 2017). Though not included in this 
project, one might hypothesize that women seek healthcare more than men and therefore would 
have a greater likelihood of being treated for chronic pain. Hirsh et al., (2014) found that gender 
of both patients and providers can affect the management of chronic pain in patients. 
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The mean age in this sample was 62 years. From the perspective of treating chronic pain, 
this was not unexpected. In those under the age of 50 and under the age of 18, the use of chronic 
opioids is not without significant concern. The current guidelines do not address the use of 
opioids in the pediatric population, and concern of dependence and/or addiction has been 
identified (Dowell et al., 2016). Older adults have more chronic conditions that worsen with age. 
For example, arthritis is a common problem seen in older adults who are not always good 
candidates for anti-inflammatories due to chronic renal or cardiovascular issues (Malec, & 
Shega, 2015). Across this sample, arthritis was a primary diagnosis.  
Although one-fourth of Kentuckians smoke tobacco (Odani et al., 2018), there was a low 
percentage of smokers in the project sample. Due to the brain’s addiction pathway, concurrent 
opioid and smoking can influence the pain response to opioids. Though the smoking sample size 
in this project was small, smokers reported more pain and higher MME per day. The shared 
acetylcholine receptors in the opioid and nicotine addiction pathways is a potential reason for 
why smoking may hinder pain management (Sutherland et al., 2016).  
The incidence of anxiety and depression as a co-morbid diagnosis among the patients in 
this sample revealed disparity between smokers and non-smokers. Independently, smokers 
without chronic pain have higher instances of anxiety and depression. Chronic pain is also 
identified with anxiety and depression, irrespective of smoking status. Therefore, when the two 
are combined it is not surprising to find that the smokers in this sample had a higher incidence of 
anxiety and depression as a comorbidity. This is supported by Ditre et al. (2015), who reported 
that smokers have higher anxiety in relation to chronic pain. What remains unclear is the 
direction of the relationship. It is possible that depression could occur as a result of chronic pain 
in patients with pain-smoking relations or vice versa. 
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Limitations  
 Several limitations were identified in the design and procedures of this project. The 
data were collected from only one clinic, limiting the generalization. Additionally, the 
sample population was relatively small (n=37), with only 19% of these patients identified as 
smokers. The population was also predominantly female (76%), which further limits the 
generalizability of the findings to males. Race and ethnicity were not a part of the 
demographic data obtained from the chart review. However, the COAT clinic 
predominantly serves a Caucasian population, which limits the findings across diverse 
ethnic backgrounds. This is a healthcare disparity among ethnicities is recognized in the 
literature (Tait & Chibnall, 2014). 
 Additionally, some patients may not have had full six data points when collecting 
pain data. Patients are required to see their PCP every 3-6 months, and therefore data 
regarding their GPS and current pain level may have been missed for months which the 
patient could not attend the clinic. This missing information may have skewed the results.  
Recommendations for Practice 
Currently, for each patient, tobacco use status is asked and readiness to quit is 
assessed at each COAT appointment. Though not fully investigated in this sample, providers 
may recognize the opportunity for brief smoking cessation intervention. It is important that 
all 5 A’s are used together to increase effectiveness and likelihood for success (Aveyard, et 
al., 2012). In fact, the US Preventative Serve Task Force (2015) gives a grade A 
recommendation advising clinicians to screen all patients for tobacco use and asses their 
readiness to quit. The 5 A’s offer an opportunity for the provider to evaluate as well as 
intervene in tobacco cessation treatment (Kruger et al., 2016; Sui et al., 2016). Providers can 
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use motivational interviewing techniques to further explore reasons why patients might be 
hesitant to quit. A theoretical framework, such as the HBM, can be used to guide interview 
techniques to encourage patients to become self-motivated (Green & Murphy, 2014).   
 Information regarding smoking cessation should be provided at each visit to all 
current and former smokers. Exposure to this information may help patients to recognize the 
implications that smoking has on their health, especially in relation to their pain. For 
example, a teaching sheet (Figure 3), developed for this project, to inform patients how 
smoking affects their pain could be distributed. Distributing this teaching sheet to patients at 
a COAT clinic can help expose them to smoking cessation information. This sheet also 
provides talking points for the provider which can contribute to the overall plan of care.  
The strategy used for assessing smoking cessation in the COAT clinic had patients 
indicate interest in smoking cessation on the intake form. Smoking cessation was to be 
discussed if the patient desired more information on this topic. Though this was not fully 
explored in the project design, one recommendation would be to assess previous quit 
attempts on the same intake form. This would streamline the process and conversation 
regarding smoking cessation.  
Providers must be familiar with available resources to help patients quit tobacco use.  
Data has shown group or individual psychological support can help people who want to quit. 
This could be actualized by utilizing the 1-800-QUIT- NOW (Patel et al., 2016; Kruger et al., 
2016). Moreover, NRT in combination with behavioral therapy can produce ideal outcomes 
regarding tobacco therapy (Fiore et al., 2008). A variety of counseling styles have helped 
smokers gain control over their behavior: motivational interviewing, cognitive behavioral 
17 
 
 
 
therapy, and acceptance and commitment therapy (Lindson‐Hawley, 2015, Spears et al., 
2017; Bricker et al., 2017).  
Depression and anxiety among chronic pain patients, especially those who smoke, 
cannot be ignored. This most prevalent comorbidity is not fully addressed among its 
relationship between tobacco and those with chronic pain. Depression and anxiety has been 
found to complicate smoking cessation attempts (Zale et al., 2016). Psychiatric services 
should be explored and offered to all patients.  
Conclusion 
Many gaps still exist when addressing smokers with concurrent opioid use. In order to 
address these gaps, more research is needed to discover the most effective way for PCPs to 
encourage smoking cessation.  The goal of chronic pain management is to achieve adequate pain 
control in patients with chronic pain. Along with a need to use the 5 A’s to their highest 
potential, there is also a need for clinicians to understand the mechanisms between smoking and 
chronic pain. When providers collaborate with smokers who experience chronic pain, positive 
outcomes can result for all parties involved. By enhancing PCP engagement in tobacco cessation 
treatment in patients with chronic pain, their disproportionate tobacco disease burden can be 
addressed.  
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Table 1. Demographic and clinical characteristics of the sample (n= 37) 
Demographic 
 
Mean (SD) or n (%) 
Age 61.9 (9.0) 
Gender 
   Male 
   Female 
 
9 (24.3%) 
28 (75.7%) 
Smoker 
   Yes 
   No 
 
7 (18.9%) 
30 (81.1%) 
Acceptable pain level (0-10)  5.16 (1.95) 
Avg Pain at Appointment (1-10) 6.1 (2.1) 
Global pain score (0-100) 30.5 (19.3) 
Morphine equivalent 
(mg/ME/day) 
 
22.77(13.1) 
 
 
 
 
 
Table 2. Comparison of pain levels among smokers and non-smokers 
 Smoker 
(n=7) 
 
Mean (SD) 
Non-smoker 
(n=30) 
 
Mean (SD) 
p 
Pain at Appointment 
(1-10) 
7.1 (1.7) 5.8 (2.2) 0.14 
Global Pain Score 
(GPS) (1-100) 
34.2 (17.4) 21.9 (20.1) 0.71 
Acceptable Pain 
Level (1-100) 
5.14 (1.5) 5.17 (2.1) 0.9 
Morphine Equivalent 
(mg/ME/day)  
26.4(12.8) 21.9(13.2) 0.42 
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Table 3. Pain Characteristics with Sub-group 
 
Variable Non-smoker  
(n=7) 
Smoker 
(n=7) 
Non-smoker 
(n=30) 
Average Pain at 
Appointment (1-10) 
7.0 7.1 5.8 
Global Pain Score 
(1-100) 
27.3 34.2 21.9 
Acceptable Pain 
Level (1-10) 
6 5.14 5.17 
Morphine 
Equivalent  
(MME) 
19.6  26.4 21.9 
 
 
 
Table 4. Morphine Milligram Equivalent (MME) Conversion table  
Medication mg per day Morphine 
Equivalent 
Morphine   
1 
 
1 
Hydrocodone   
1 
 
1 
Oxycodone  
1 
 
1.5 
Tramadol  
1 
 
0.1 
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Figure 1. Global Pain Scale  
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Figure 2. Teaching Sheet 
 
Why Smoking Will Worsen Your Chronic Pain 
Short-term relief from nicotine brings long-term problems 
 
Do you look to smoking for relief from a bad back? Or aching joints? Or 
abdominal pain?  
Cleveland Clinic is a non-profit academic medical center. 
Advertising on our site helps support our mission. We do not endorse 
non-Cleveland Clinic products or services. Think twice before lighting 
up that cigarette. “Nicotine-induced pain relief is short-term. Over time, 
smoking may actually worsen your pain,” says pain management 
specialist Crawford Barnett, MD. 
 
Smokers are nearly three times as likely to get lower back 
pain. Smoking may aggravate abdominal pain and joint pain, as well. In fact, smoking may increase pain 
sensitivity in general. About 18% of people in the US are smokers, according to the Centers for Disease 
Control and Prevention. Yet smokers make up more than 50 percent of patients who seek pain treatment. 
How smoking hurts 
The nicotine in tobacco can trick the body into feeling good — at first. It triggers the release of 
chemicals, like dopamine, which give off a satisfying, “reward” sensation. It’s what makes smoking so addictive. 
But that same tobacco also impairs the delivery of oxygen-rich blood to bones and tissues. Decreasing blood 
and nutrient flow can cause degeneration, particularly in discs of the spine, which already have more limited 
blood flow. The result can be lower back pain and sometimes osteoporosis. 
 
Physicians also link smoking with fatigue and slower healing, factors that make painful conditions more 
prominent. Researchers are exploring even more physiological reasons why smoking makes people 
with fibromyalgia, arthritis and other chronic pain hurt more.  
“Almost everyone knows smoking can cause cancer, lung disease and cardiovascular disease,” says 
Dr. Barnett. “But not everyone realizes that smoking can make your pain worse. ”To make matters worse, when 
smokers suffer from debilitating pain, potentially life-changing treatments may not work. “Smokers aren’t the 
best candidates for implantable devices such as neurostimulators, which block pain sensation,” says Dr. 
Barnett. “Smoking impairs the immune system and increases the risk of infection after surgery. 
How to get Started 
Dr. Barnett actively counsels patients to quit smoking. “You may look to cigarettes for help coping with pain, 
anxiety or stress, but there are healthier ways to do that,” he says. Here’s what he suggests: 
 
• Schedule your “quit day.” 
• Ask your primary care doctor about medication or nicotine replacement products. 
• Consider additional treatments like acupuncture or hypnosis. 
• Call 1-800-QUIT-NOW for free help from trained coaches. 
• Get support from family and friends, and join a support group. 
• Take a walk whenever you feel the urge to smoke. 
You can also start a new exercise program. Exercise activates endorphins, chemicals in the brain that 
can help block or lessen pain. “Quitting smoking may be one of the most significant things you can do to both 
improve your health and manage your pain,” says Dr. Barnett. 
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Figure 3.  COAT Clinic Contract 
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Figure 4. The 5 A’s of Smoking Cessation 
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Figure 5. Average GPS scores  
 
GLOBAL PAIN SCALE (1-100) 
 
Smokers 
(n=7) 
Non-Smokers 
(n=30) 
June 32 18 
July 30.2 19 
August 30 18 
September 36.5 19.5 
October 26 27 
November 24.75 21 
Average       29.9  21.0 
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Figure 6. Average Pain at time of Appointment (1-10) 
Month 
Smokers 
(n=7) 
 
Non- Smokers 
(n=30) 
 
June 6.75 5.5 
July 6.4 5.7 
August 6.75 5.6 
September 7.5 5.4 
October 6.25 6.1 
November 6.75 6.4 
Average 6.73              5.79 
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Figure 7. Pain Location 
Location Total Smoker 
N=7 
Non-Smoker 
N=30 
Legs 15 5 (86%) 10 (33%) 
Back 13 3 (43%) 10 (33%) 
Shoulder 11 2 (29%) 9 (30%) 
Feet 10 1 (14%) 9 (30%) 
Ankles 5 1 (14%) 4 (13%) 
Arms 5 1 (14%) 4 (13%) 
Neck 5 1 (14%) 4 (13%) 
Hips 4 1 (14%) 3 (10%) 
Abdomen 2 1(14%) 1 (3%) 
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Figure 8. Co-morbidities (n=37) 
 
Dx TOTAL (n=37) 
 
Smoker (n=7) Non-Smoker (n=30) 
HTN 21 (57%) 4 (57%) 17 (57%) 
HLD  20 (54%) 4 (57%) 16 (53%) 
GERD 16 (43%) 2 (29%) 14 (47%)  
COPD 11 (30%) 2 (29%)  9 (30%)  
DM 21 (57%) 4 (57%) 17 (57%) 
Asthma 8 (22%) 2 (29%)  6 (20%) 
Neuropathy 4 (11%) 2 (29%)  2 (7%) 
CAD 7 (19%) 1 (14%) 6 (20%)  
Dep/Anxiety 15 (41%) 5 (71%) 10 (33%) 
GOUT 6 1(6%) 0 6 (20%) 
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Figure 9. Diagnoses 
 
Diagnosis 
 
Total 
N= 37 
Smoker 
N=7 
Non-Smoker 
N=30 
Arthritis 11 3 (43%) 8 (27%) 
DDD 2 1 (14%) 1 (3%) 
Generalized pain 9 4 (57%) 5 (16%) 
Arthropathy 3 0 3 (10%) 
Neuropathy 3 1 (14%) 2 (7%) 
Cervicalgia 2 0 2 (7%) 
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Figure 10. CDC Guideline for Prescribing Opioids 
 
 
 
